Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Atrial Fibrillation

Treatments

Drug: Rivaroxaban

Drug: Dabigatran

Drug: Warfarin

Drug: Apixaban

Study type

Observational

Funder types

Industry

Identifiers

NCT02754154

CV185-433

Details and patient eligibility

About

The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.

Enrollment

321,182 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients ≥18 years old as of the index date
At least 1 diagnosis of atrial fibrillation in the 12 months prior to or on index date, identified by any medical claim
At least one year of baseline period and continuous enrollment for at least 12 months prior to index date Individuals with NVAF who were using oral anticoagulants (i.e., warfarin, dabigatran, rivaroxaban and apixaban) within the study period beginning Jan 1, 2012 through December 31, 2013 or last date of the last data cut available at the time of execution of the study

Exclusion criteria

Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral stenosis, Venous thromboembolism(VTE), heart surgery, and endocarditis during the baseline period any time prior to or on index date
Patients with any evidence of pregnancy at any time during the baseline will be excluded